Co-culturing Hep3B treated by siRNA anti PDGFR-α, delivered by the commercial DharmaFECT, resulted in a significant reduction of LX2 proliferation and expression of α-SMA/collagen type I. This observation indicates the relevance of hepatocytes in the process of liver fibrosis [61] and suggests that the PDGFR-α silencing directly in HSC may potentially be of therapeutic interest. Here, PDGFRA is linked to Hepatic fibrosis.